Labetalol (versus unexposed) updated on 12-17-2024

Neonatal medical care

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14403
R57211		 Xiang, 2020 Admission to Neonatal Intensive Care Unit during pregnancy (anytime or not specified) randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication 2.23 [1.21;4.12] C 38/124   20/121 58 124
ref
S14341
R56742		 Thewissen (Controls unexposed, disease free), 2017 Mechanical ventilation during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 1.75 [0.52;5.84] C
excluded (control group) 		14/22   11/22 25 22
ref
S14342
R56745		 Thewissen (Controls unexposed, sick), 2017 Mechanical ventilation during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 1.46 [0.44;4.88] C 14/22   12/22 26 22
ref
Total 2 studies 2.05 [1.18;3.53] 84 146
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Xiang, 2020Xiang, 2020 2.23[1.21; 4.12]5812480%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Thewissen (Controls unexposed, sick), 2017Thewissen, 2017 1 1.46[0.44; 4.88]262220%ROB confusion: criticalROB selection: unclearROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 2.05[1.18; 3.53]841460.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.46[0.44; 4.88]2622 -NAThewissen (Controls unexposed, sick), 2017 1 case control studiescase control studies 0 RCTRCT 2.23[1.21; 4.12]58124 -NAXiang, 2020 1 Type of controls unexposed, sickunexposed, sick 2.05[1.18; 3.53]841460%NAXiang, 2020 Thewissen (Controls unexposed, sick), 2017 2 Tags Adjustment   - No  - No 1.46[0.44; 4.88]2622 -NAThewissen (Controls unexposed, sick), 2017 1   - Randomisation  - Randomisation 2.23[1.21; 4.12]58124 -NAXiang, 2020 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.46[0.44; 4.88]2622 -NAThewissen (Controls unexposed, sick), 2017 1   - Only chronic hypertension indication  - Only chronic hypertension indication 2.23[1.21; 4.12]58124 -NAXiang, 2020 1 MatchedMatched 1.46[0.44; 4.88]2622 -NAThewissen (Controls unexposed, sick), 2017 1 All studiesAll studies 2.05[1.18; 3.53]841460%NAXiang, 2020 Thewissen (Controls unexposed, sick), 2017 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 14341

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.75[0.52; 5.84]2522 -NAThewissen (Controls unexposed, disease free), 2017 1 unexposed, sick controlsunexposed, sick controls 2.05[1.18; 3.53]841460%NAXiang, 2020 Thewissen (Controls unexposed, sick), 2017 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Firoz (Admission to Neonatal intensive care u ...Firoz (Admission to Neonatal intensive care unit (Labetalol iv versus Nifedipine)) 1.00[0.18; 5.56]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Firoz (Admission to Neonatal intensive care u ...Firoz (Admission to Neonatal intensive care unit (Labetalol versus Methyldopa)) 1.06[0.66; 1.72]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Bone - GESTATIONAL HYPERTENSION (Neonatal car ...Bone - GESTATIONAL HYPERTENSION (Neonatal care unit admission) 1.00[0.52; 1.90]34%-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bone - GESTATIONAL HYPERTENSION (Neonatal car ...Bone - GESTATIONAL HYPERTENSION (Neonatal care unit admission) 0.90[0.53; 1.45]39%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (Neonatal intensive care unit (NICU) admission) 1.30[0.88; 1.96]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT5 Shi (Intravenous Labetalol) - GESTATIONAL HYP ...Shi (Intravenous Labetalol) - GESTATIONAL HYPERTENSION (Neonatal Intensive Care Unit admission (versus oral nifedipine)) 0.99[0.62; 1.59]0%-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT3 metaPregmetaPreg 2.05[1.18; 3.53]0%146----Xiang, 2020 Thewissen (Controls unexposed, sick), 2017 20.510.01.0